Eli Lilly & Co. Sees Unusually High Options Volume (LLY)
Shares of Eli Lilly & Co. (NYSE:LLY) saw some unusual options trading activity on Thursday. Investors bought 9,215 put options on the company, Stock Ratings Network reports. This represents an increase of 186% compared to the typical daily volume of 3,217 put options.
Several analysts have recently commented on the stock. Analysts at Leerink Swann raised their price target on shares of Eli Lilly & Co. (NYSE:LLY) from $61.00 to $62.00 in a research note to investors on Friday, September 27th. They now have an “outperform” rating on the stock. Separately, analysts at BMO Capital Markets cut their price target on shares of Eli Lilly & Co. (NYSE:LLY) from $55.00 to $50.00 in a research note to investors on Friday, September 27th. They now have a “market perform” rating on the stock. Finally, analysts at Guggenheim cut their EPS estimates on shares of Eli Lilly & Co. (NYSE:LLY) in a research note on Friday. They now have an “outperform” rating and a $61.00 price target on the stock. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the company’s stock. Eli Lilly & Co. has a consensus rating of “Buy” and an average price target of $57.25.
Shares of Eli Lilly & Co. (NYSE:LLY) traded down 3.44% during mid-day trading on Thursday, hitting $48.80. 15,008,044 shares of the company’s stock traded hands. Eli Lilly & Co. has a 52-week low of $44.88 and a 52-week high of $58.40. The stock’s 50-day moving average is $52.47 and its 200-day moving average is $53.48. The company has a market cap of $52.714 billion and a price-to-earnings ratio of 11.35.
Eli Lilly & Co. (NYSE:LLY) last issued its quarterly earnings data on Wednesday, July 24th. The company reported $1.16 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.01 by $0.15. The company had revenue of $5.93 billion for the quarter, compared to the consensus estimate of $5.82 billion. During the same quarter last year, the company posted $0.83 earnings per share. Eli Lilly & Co.’s revenue was up 5.9% compared to the same quarter last year. Analysts expect that Eli Lilly & Co. will post $4.14 EPS for the current fiscal year.
Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.